Swiss life-science company Lonza announced on Tuesday that it is to
strengthen the production of oligonucleotides - an emerging new
class of therapeutics consisting of short nucleic acid chains
interfering in the processing of genetic...
Nabi Biopharmaceuticals saw biopharmaceutical product sales -
driven by strong growth in sales of Nabi-HB - reaching record
levels of $89.5 million (€83m) in 2002, a 22 per cent increase from